Amneal Pharmaceuticals (AMRX) Following Its Biosimilars Push And The Fair Value Debate
Amneal Pharmaceuticals stock reacts to recent performance metrics
Amneal Pharmaceuticals (AMRX) has drawn fresh attention as its stock trades around $17.87. Recent performance data and profitability metrics are giving investors new context for assessing this US based generics and specialty drug maker.
Recent trading has cooled slightly, with the share price down 3.30% over the past 30 days and 1.05% over the last session. Amneal Pharmaceuticals still shows strong momentum, reflected in a 41.15% year to date share price return and an 87.12% 1 year total shareholder return.
Scan other health and value focused opportunities showing similar momentum to Amneal Pharmaceuticals by reviewing our hand picked 53 high quality undervalued stocks.
Amneal Pharmaceuticals trades at a double discount, both to analyst targets and to one estimate of intrinsic value, even after a strong 1 year run. Is the market too cautious, or is that gap earned?
Most Popular Narrative: 28.5% Undervalued
Amneal Pharmaceuticals last closed at $17.87, while the most followed narrative anchors on a Fair Value of $25, which frames a sizeable valuation gap.
The acquisition of Kashiv BioSciences creates a fully integrated biosimilars platform, combining in-house R&D, manufacturing across the U.S. and India, and Amneal Pharmaceuticals commercial scale. Management expects this to support multiple biosimilar launches per year and influence long term revenue and earnings growth.
Want to see what this biosimilar build out implies for Amneal Pharmaceuticals earnings, margins and future valuation multiples? The full narrative spells out the revenue path, profit profile and required market pricing that underpin that $25 Fair Value.
Result: Fair Value of $25 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this bullish Amneal Pharmaceuticals narrative could unravel if biosimilar competition limits the company’s share gains, or if higher capital spending weighs on margins and cash generation.
Find out about the key risks to this Amneal Pharmaceuticals narrative.
Another View on Amneal Pharmaceuticals valuation
The first narrative leans on future earnings and a Fair Value of $25, yet today Amneal Pharmaceuticals trades on a P/E of 39.6x. That is far above the US Pharmaceuticals industry at 16.5x, peers at 18.8x and even our fair ratio of 31.2x. This points to meaningful valuation risk if expectations slip.
For investors comparing these signals, the gap between the current P/E and the fair ratio raises a simple question. Is the premium on Amneal Pharmaceuticals a price you are comfortable paying for the growth story that has been outlined so far, or do you prefer to wait for the valuation to move closer to the fair ratio?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Sentiment on Amneal Pharmaceuticals here is mixed, with genuine risks and clear potential rewards in play. It makes sense to review the details yourself and move quickly to shape an independent view using the 3 key rewards and 3 important warning signs.
Looking for more investment ideas beyond Amneal Pharmaceuticals?
If Amneal Pharmaceuticals has sharpened your focus on opportunities, do not stop here. Use the Simply Wall Street Screener to quickly spot fresh ideas across different styles.
- Target potential mispriced opportunities by reviewing our hand picked 53 high quality undervalued stocks that combine quality fundamentals with appealing valuations.
- Strengthen the resilience of your portfolio by scanning our list of solid balance sheet and fundamentals (53 results) for companies with sturdier financial foundations.
- Get ahead of the crowd by tracking our 21 high quality undiscovered gems that many investors may be overlooking right now.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com